ADAPTcycle – adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate risk HR+/HER2- early breast cancer. (March 2019) - Harbeck, N.; Gluz, O.; Christgen, M.; Graeser, M.; Hilpert, F.; Kreipe, H.H.; Nitz, U.; Kates, R.; Schinkoethe, T.; Kuemmel, S.; ,